<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943709</url>
  </required_header>
  <id_info>
    <org_study_id>060601</org_study_id>
    <secondary_id>AVENTIS-CINJ-060601</secondary_id>
    <secondary_id>0220070268</secondary_id>
    <secondary_id>CDR0000648982</secondary_id>
    <secondary_id>P30CA072720</secondary_id>
    <nct_id>NCT00943709</nct_id>
  </id_info>
  <brief_title>Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia</brief_title>
  <official_title>Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Controlling blood sugar levels may be effective in preventing infections in&#xD;
      patients receiving chemotherapy for acute myeloid leukemia or acute lymphoblastic leukemia.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying how well controlling blood sugar levels&#xD;
      works in preventing infection in patients with acute myeloid leukemia or acute lymphoblastic&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine whether intensive glycemic control over an eight week time period will&#xD;
           decrease the incidence of infections from initiation of chemotherapy treatment in&#xD;
           patients with acute myeloid leukemia or acute lymphoblastic leukemia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare the number of episodes of infection.&#xD;
&#xD;
        -  To compare the duration of neutropenia.&#xD;
&#xD;
        -  To compare the number of days of bacteremia/fungemia.&#xD;
&#xD;
        -  To compare the number of days of fever.&#xD;
&#xD;
        -  To compare the duration of nutrition.&#xD;
&#xD;
        -  To compare the duration of mucositis.&#xD;
&#xD;
        -  To compare the duration of hospital stay.&#xD;
&#xD;
        -  To compare the duration of antibiotic use.&#xD;
&#xD;
        -  To compare the incidence of thromboembolic events.&#xD;
&#xD;
        -  To compare body weight changes.&#xD;
&#xD;
        -  To compare the median survival.&#xD;
&#xD;
        -  To compare the remission rate with induction or salvage chemotherapy.&#xD;
&#xD;
        -  To conduct comparative analysis between intervention and standard of care groups of mean&#xD;
           daily capillary blood glucose monitoring.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (intensive glycemic control): Patients with goal blood glucose 80-140 mg/dL&#xD;
           receive the Robert Wood Johnson University Hospital IV insulin infusion protocol to&#xD;
           maintain blood glucoses in the target range. Beginning 24 hours after maintenance of&#xD;
           oral or enteral feedings patients receive an intensive regimen of insulin glargine and&#xD;
           insulin glulisine (Apidra™) subcutaneously for 4 weeks as needed. Patients may also&#xD;
           receive insulin in the total parenteral nutrition (TPN) mixture.&#xD;
&#xD;
        -  Arm II (standard care control): Patients with goal blood glucose &lt; 250 mg/dL are started&#xD;
           on subcutaneous insulin sliding scale at the discretion of the treating physician with&#xD;
           blood glucose monitoring and adjustment according to the insulin sliding scale. Insulin&#xD;
           may also be added to TPN if needed at the investigator's discretion.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of accrual&#xD;
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of new infections</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of infection</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of neutropenia</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of bacteremia/fungemia</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of fever</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of nutrition</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mucositis</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic use</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thromboembolic events</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight changes</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate with induction or salvage chemotherapy</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative analysis between intervention and standard of care groups of mean daily capillary blood glucose monitoring</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with goal blood glucose 80-14 mg/dL receive the Robert Wood Johnson Hospital IV insulin infusion protocol followed by insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with goal blood glucose &lt; 250 mg/dL are started on subcutaneous insulin sliding scale at the discretion of the treating physician with blood glucose monitoring and adjustment according to the insulin sliding scale.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>insulin glargine recombinant</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic insulin</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed acute myeloid leukemia or acute lymphoid leukemia&#xD;
&#xD;
               -  Newly diagnosed or relapsed disease&#xD;
&#xD;
          -  Undergoing induction or salvage chemotherapy treatment&#xD;
&#xD;
          -  Must demonstrate 2 random blood sugars of ≥ 140 mg/dL while on total parenteral&#xD;
             nutrition (TPN) OR 2 preprandial sugars of ≥ 140 mg/dL if patient is not on TPN&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-3&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Prior diagnosis of diabetes mellitus allowed&#xD;
&#xD;
          -  No known history of an allergy to insulin&#xD;
&#xD;
          -  No documented active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Concurrent corticosteroids allowed&#xD;
&#xD;
          -  No concurrent oral hypoglycemic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mecide Gharibo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperglycemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

